IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PIETRANTONIO, FILIPPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 17.630
AS - Asia 13.168
NA - Nord America 12.712
SA - Sud America 1.252
AF - Africa 277
OC - Oceania 133
Continente sconosciuto - Info sul continente non disponibili 11
Totale 45.183
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.207
DE - Germania 8.124
CN - Cina 4.543
SG - Singapore 3.125
IT - Italia 2.659
GB - Regno Unito 2.521
HK - Hong Kong 1.065
BD - Bangladesh 1.033
BR - Brasile 959
SE - Svezia 818
RU - Federazione Russa 811
VN - Vietnam 807
JP - Giappone 786
FR - Francia 655
IN - India 552
IE - Irlanda 365
CA - Canada 357
NL - Olanda 349
ES - Italia 273
FI - Finlandia 248
TR - Turchia 221
ID - Indonesia 205
KR - Corea 187
AU - Australia 111
TW - Taiwan 105
TH - Thailandia 98
AR - Argentina 97
UA - Ucraina 95
MX - Messico 89
CH - Svizzera 88
DK - Danimarca 87
BE - Belgio 85
CI - Costa d'Avorio 78
PL - Polonia 71
AT - Austria 70
IQ - Iraq 63
PH - Filippine 57
PT - Portogallo 54
RO - Romania 53
ZA - Sudafrica 52
CL - Cile 47
EG - Egitto 43
PK - Pakistan 43
SA - Arabia Saudita 41
CO - Colombia 37
IR - Iran 37
EC - Ecuador 36
GR - Grecia 34
NO - Norvegia 32
JO - Giordania 26
PE - Perù 26
UZ - Uzbekistan 26
MA - Marocco 24
CZ - Repubblica Ceca 22
NZ - Nuova Zelanda 22
IL - Israele 20
VE - Venezuela 20
NP - Nepal 18
MY - Malesia 17
TN - Tunisia 16
AE - Emirati Arabi Uniti 15
DZ - Algeria 15
KE - Kenya 15
HU - Ungheria 14
BG - Bulgaria 13
KZ - Kazakistan 13
HR - Croazia 12
BO - Bolivia 11
CR - Costa Rica 10
BA - Bosnia-Erzegovina 9
PY - Paraguay 9
LB - Libano 8
OM - Oman 8
RS - Serbia 8
UY - Uruguay 8
AL - Albania 7
AZ - Azerbaigian 7
HN - Honduras 7
JM - Giamaica 7
LV - Lettonia 7
NG - Nigeria 7
SI - Slovenia 7
DO - Repubblica Dominicana 6
KG - Kirghizistan 6
ME - Montenegro 6
MK - Macedonia 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
CY - Cipro 5
ET - Etiopia 5
GE - Georgia 5
GT - Guatemala 5
KW - Kuwait 5
LT - Lituania 5
MD - Moldavia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
IS - Islanda 4
LU - Lussemburgo 4
MU - Mauritius 4
PA - Panama 4
Totale 45.118
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 7.191
Southend 2.057
Singapore 1.756
Ashburn 1.460
Chandler 965
Hong Kong 898
Milan 703
Beijing 697
San Jose 679
Fairfield 585
Dallas 478
Council Bluffs 382
Dublin 362
Princeton 361
Seattle 355
Wilmington 354
Los Angeles 346
New York 345
Shanghai 309
Houston 304
Tokyo 283
Santa Clara 280
Woodbridge 277
Cambridge 271
Ho Chi Minh City 244
Hanover 239
Guangzhou 232
Hanoi 226
Nanjing 224
Ann Arbor 210
Munich 190
Lauterbourg 184
Bengaluru 183
Redwood City 178
Moscow 177
Buffalo 173
Dearborn 165
Rome 160
Helsinki 156
Jakarta 150
Des Moines 148
Toronto 147
Boardman 137
Hefei 130
Phoenix 129
Istanbul 110
Jinan 108
Columbus 105
São Paulo 101
Shenyang 91
The Dalles 91
Chicago 86
Naples 86
Hangzhou 84
Tianjin 80
Abidjan 78
London 73
Seoul 69
Zhengzhou 68
Madrid 66
San Diego 60
Duncan 59
Cangzhou 57
Nanchang 56
Berlin 55
Grafing 55
Turin 54
Brussels 53
Changsha 53
Fuzhou 53
Amsterdam 52
Chengdu 50
Shenzhen 50
Wuhan 50
Taipei 49
Hebei 47
Nuremberg 47
Bari 46
Da Nang 46
Montreal 45
San Francisco 43
Atlanta 42
Central District 41
Falls Church 40
Barcelona 39
Bangkok 38
Bologna 38
Paris 38
Turku 38
Pune 36
Boston 34
Haiphong 34
Ottawa 34
Silver Spring 34
Hyderabad 33
Osaka 33
Mumbai 32
Warsaw 32
Washington 32
Ankara 30
Totale 28.534
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 4.588
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 703
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 638
Gender influence on professional satisfaction and gender issue perception among young oncologists : a survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) 586
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 514
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy 478
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 416
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 395
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 370
Trattamento di seconda linea con FOLFIRI e aflibercept in paziente con adenocarcinoma del colon destro avanzato e BRAF mutato = Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer 369
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase 341
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 341
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : A clinical and translational study 340
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 339
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients with Potentially Resectable Colorectal Cancer Liver Metastases 323
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 311
AtezoTRIBE : a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 303
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status 302
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan 301
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 294
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient 291
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 287
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 287
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 287
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel : A Translational Analysis from the ITACA-S Trial. Oncologist 285
Adjuvant treatment of colorectal cancer in the elderly : where do we come from and where are we going? 282
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 279
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials 276
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial 275
The landscape of actionable gene fusions in colorectal cancer 275
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan 274
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis 273
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer 270
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 269
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? 265
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer 260
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 260
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers 259
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 256
Clinical Behavior and Treatment Response of Epstein-Barr Virus–Positive Metastatic Gastric Cancer : Implications for the Development of Future Trials 256
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 255
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation 254
Toward the molecular dissection of peritoneal pseudomyxoma 254
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 252
Targeting cancer metabolism : Dietary and pharmacologic interventions 252
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens 251
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 250
Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens 249
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer 247
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial) 246
TP53 mutations in advanced colorectal cancer : the dark side of the moon 245
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 243
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 241
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma 241
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer : a pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 238
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 238
Role of cMET in the development and progression of colorectal cancer 235
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis 235
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma : Myth or Reality? 235
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis 234
Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial 234
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases 233
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 233
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients : the AMNESIA Case-Control Study 232
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer : A Literature-Based Systematic Review and Meta-Analysis 228
Tremelimumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer : The multicentre, single-arm, multi-cohort, phase II INFINITY study 228
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study 227
Atypical RAS Mutations in Metastatic Colorectal Cancer 226
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients : A Multi-institutional Analysis 225
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 223
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 222
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 221
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 220
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : challenging drug label to light up new hope 219
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 219
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 219
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer 219
Genomic markers of resistance to targeted treatments in gastric cancer : potential new treatment strategies 218
Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer 218
Role of BAX for outcome prediction in gastrointestinal malignancies 217
Role of MGMT as biomarker in colorectal cancer 216
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer 215
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer : Real-World Data from the RAMoss Study 215
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil : a meta-analysis of published trials 215
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 215
The landscape of d16HER2 splice variant expression across HER2-positive cancers 214
BRAF in metastatic colorectal cancer : the future starts now 213
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 213
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 212
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 212
Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues 211
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy : A pre-specified secondary analysis of the Valentino study 211
LightSNiP assay is a good strategy for pharmacogenetics test 210
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 206
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression : lesson Learned for Future Trials With EGFR/MET Dual Inhibition 206
Personalized therapeutic strategies in HER2-driven gastric cancer 206
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 205
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy : Implication for further clinical research 204
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study 204
Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer : A systematic review and meta-analysis of published trials 203
Totale 31.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.399
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.399
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021265 0 0 0 0 0 0 0 0 0 0 0 265
2021/20223.945 337 216 241 313 365 254 238 256 371 491 215 648
2022/20233.818 451 426 341 338 300 660 140 291 404 88 269 110
2023/20247.563 124 210 202 240 525 296 1.154 1.001 544 1.033 1.089 1.145
2024/20258.754 1.057 1.085 850 981 460 402 427 591 411 592 642 1.256
2025/202613.516 1.286 868 1.295 838 1.150 806 1.653 559 1.236 900 1.865 1.060
Totale 46.709